ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

An MRI-based AI tool shows high accuracy in differentiating Parkinsonian syndromes in a large prospective study. Learn more.

Annexon Inc. research and ratings by Barron's. View ANNX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by dopaminergic neuron loss and the accumulation of abnormal synuclein. PD presents both ...

Parkinson’s Disease Causes, Symptoms, and Treatment Parkinson’s disease (PD) is one of the fastest-growing neurological ...

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics announced the results of its 2025 Annual General Meeting, ...

In an exclusive interview, Alterity Therapeutics’ ( ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more. Published ...

Chennai: A new AI-enabled deep brain stimulation (DBS) device, one that can read brain signals and adjust itself, will be ...

Rare diseases reveal that our sense of identity rests on fragile biological infrastructure, much of it operating outside conscious awareness. Movement, balance, motivation, emotional tone—these feel ...

The α-synuclein protein can adopt several different conformations that cause neurodegeneration. Different α-synuclein conformers cause at least three distinct α-synucleinopathies: multiple system ...

A large international study involving nearly 700 participants reveals that women with a precursor condition to Parkinson's disease show significantly less brain atrophy—decreased cortical thickness in ...

Women with a precursor condition to Parkinson’s disease showed significantly less brain atrophy than their male counterparts despite similar clinical severity, according to an October study published ...